positions on the Committee membership that will become vacant on January 3, 2007.

**DATES:** Nominations for membership on the Committee must be received no later than May 30, 2006.

**ADDRESSES:** Nominations should be mailed or delivered to: Dr. Bernard Schwetz, Director, Office for Human Research Protections, Department of Health and Human Services, 1101 Wootton Parkway, Suite 200; Rockville, MD 20852. Nominations will not be accepted by e-mail or by facsimile.

**FOR FURTHER INFORMATION CONTACT:** Ms. Catherine Slatinshek, Executive Director, SACHRP, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852, telephone: 1–240–453–6900. A copy of the Committee charter and list of the current membership can be obtained by contacting Ms. Slatinshek or by accessing the SACHRP Web site at *http://www.hhs.gov/ohrp/sachrp,* or requesting via e-mail at *sachrp@osophs.dhhs.gov.*

**SUPPLEMENTARY INFORMATION:** The Committee shall advise on matters pertaining to the continuance and improvement of functions within the authority of HHS directed toward protections for human subjects in research. Specifically, the Committee will provide advice relating to the responsible conduct of research involving human subjects with particular emphasis on: Special populations, such as neonates and children, prisoners, and the decisionally impaired; pregnant women, embryos, and fetuses; individuals and populations in international studies; populations in which there are individually identifiable samples, data, or information; and investigator conflicts of interest.

In addition, the Committee is responsible for reviewing selected ongoing work and planned activities of the OHRP and other offices/agencies within HHS responsible for human subjects protection. These evaluations may include, but are not limited to, a review of assurance systems, the application of minimal research risk standards, the granting of waivers, education programs sponsored by OHRP, and the ongoing monitoring and oversight of institutional review boards and the institutions that sponsor research.

**Nominations**

The Office for Human Research Protections is requesting nominations to fill four positions for voting members of SACHRP. The positions will become vacant on January 3, 2007. Nominations of potential candidates for consideration are being sought from a wide array of fields, including, but not limited to public health and medicine, behavioral and social sciences, health administration, and biomedical ethics. To qualify for consideration of appointment to the Committee, an individual must possess demonstrated experience and expertise in any of the several disciplines and fields pertinent to human subjects protection and/or clinical research.

The individuals selected for appointment to the Committee will serve as voting members. The individuals selected for appointment to the Committee can be invited to serve a term of up to four years. Committee members receive a stipend and, when applicable, reimbursement for per diem and any travel expenses incurred, for attending Committee meetings and conducting other business in the interest of the Committee.

Nominations should be typewritten. The following information should be included in the package of material submitted for each individual being nominated for consideration: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination (*i.e.*, specific attributes which qualify the nominee for service in this capacity), and a statement that the nominee is willing to serve as a member of the Committee; (2) the nominator's name, address, and daytime telephone number, and the home and/or work address, telephone number, and e-mail address of the individual being nominated; and (3) a current copy of the nominee's curriculum vitae. The names of Federal employees should not be nominated for consideration of appointment to this Committee.

The Department makes every effort to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee's function. Every effort is made to ensure that a broad representation of geographic areas, females, ethnic and minority groups, and the disabled are given consideration for membership on HHS Federal advisory committees. Appointment to this Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status.

Nominations must state that the nominee is willing to serve as a member of SACHRP and appears to have no conflict of interest that would preclude membership. Potential candidates are required to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest.

Dated: April 21, 2006.

**Bernard A. Schwetz,**

*Director, Office for Human Research Protections, Executive Secretary, Secretary's Advisory Committee on Human Research Protections.*

[FR Doc. E6–6311 Filed 4–26–06; 8:45 am]

**BILLING CODE 4150–36–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### National Center for Injury Prevention and Control Initial Review Group

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting:

*Name:* National Center for Injury Prevention and Control (NCIPC) Initial Review Group (IRG)

*Times and Dates:* 10 a.m.–10:30 p.m., May 23, 2006. 8 a.m.–6:30 p.m., May 24, 2006. 8:30 a.m.–6 p.m., May 25, 2006.

*Place:* Doubletree Club Atlanta Airport, 3400 Norman Berry Drive, Atlanta, GA 30344.

*Status:* Open: 10 a.m.–11 a.m., May 23, 2006, Closed: 11 a.m.–10:30 p.m., May 23, 2006, Closed: 8 a.m.–6:30 p.m., May 24, 2006, Closed: 8:30 a.m.–6 p.m., May 25, 2006.

*Purpose:* This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focuses on prevention and control.

*Matters to be Discussed:* Agenda items include an overview of the injury program, discussion of the review process and panelists' responsibilities, and the review of and vote on applications. Beginning at 11 a.m., May 23, through 6 p.m., May 25, the Group will review individual research grant and cooperative agreement applications submitted in response to two Fiscal Year 2006 Requests for Applications related to the following individual research announcements: #06008, Urban Partnership Academic Center of Excellent and #06006, Parenting Programs in the Prevention of Child Maltreatment. This portion of the meeting will be closed to the public in accordance with provisions set forth in

section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to section 10(d) of Public Law 92–463.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Gwendolyn H. Cattledge, Ph.D., M.S.E.H., Executive Secretary, NCIPC IRG, CDC, 4770 Buford Highway, NE., M/S K02, Atlanta, Georgia 30341–3724, telephone (770) 488–1430.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 20, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6–6349 Filed 4–26–06; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2006F–0059]**

### Danisco USA, Inc.; Filing of Food Additive Petition; Amendment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Danisco USA, Inc., to indicate that the petition proposes to amend the food additive regulations at 21 CFR 172.841 by incorporating by reference the specifications for polydextrose in the 5th edition of the Food Chemicals Codex (FCC), 2003.

**ADDRESSES:** Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Paul C. DeLeo, Center for Food Safety and Applied Nutrition (HFS–265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740–3835, 301–436–1302.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of February 15, 2006 (71 FR 7975), FDA announced that a food additive petition (FAP 6A4763) had been filed by Danisco USA, Inc., 440 Saw Mill River Rd., Ardsley, NY 10502–2605. The petition proposed to amend the food additive regulations in § 172.841 Polydextrose (21 CFR 172.841) to provide for the safe use of polydextrose as a bulking agent, formulation aid, humectant, and texturizer in all foods, except meat and poultry. After publication of the filing notice, FDA learned that the petition also proposed to update § 172.841 by incorporating by reference the specifications for polydextrose in the FCC, 5th ed., 2003. Currently, § 172.841 incorporates by reference the specifications of FCC, 4th ed., 1996.

The agency compared specifications in the monograph for polydextrose in the 4th and 5th editions of the FCC and found that the 5th edition retains the lead limit of 0.5 milligram(mg)/kilogram(kg), but no longer lists a specification limit of 5 mg/kg for heavy metals as lead. The 5th edition of the FCC eliminated the heavy metals as lead test from most monographs in favor of including individual specifications for relevant heavy metals. In addition, the 5th edition added a nickel specification of 2 mg/kg for hydrogenated polydextrose, as well as modified the pH specification of a 10 percent solution of untreated polydextrose from ''not less than 2.5'' (4th edition) to ''between 2.5 and 7.0'' (5th edition). The name of the specification for 5–Hydroxymethylfurfural has also changed from ''5–Hydroxymethylfurfural'' (4th edition) to ''5–Hydroxymethylfurfural and Related Compounds'' (5th edition), although the test and equation used to determine the level have remained the same. The agency has placed copies of the polydextrose monograph in the 4th and 5th editions of the FCC on public display at the Division of Dockets Management (see **ADDRESSES**) for public review.

Dated: March 30, 2006.

**Laura M. Tarantino,**

*Director, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition.*

[FR Doc. E6–6370 Filed 4–26–06; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2005D–0202]**

### Guidance for Industry on Bar Code Label Requirements—Questions and Answers; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ''Bar Code Label Requirements—Questions and Answers.'' FDA regulations require certain human drug and biological products to have on their labels a linear bar code that identifies the drug's National Drug Code (NDC) number. We have received several inquiries about how the requirements apply to specific products or circumstances. The purpose of the guidance is to respond to the questions.

**DATES:** Submit written or electronic comments on agency guidances at any time.

**ADDRESSES:** Submit written requests for single copies of this guidance to the Division of Drug Information (HFD–240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments*. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

**FOR FURTHER INFORMATION CONTACT:** *For products regulated by the Center for Drug Evaluation and Research*: Valerie L. Whipp, Center for Drug Evaluation and Research (HFD–310), Food and Drug Administration, 11919 Rockville Pike, Rockville, MD 20852, 301–827–8963. *For products regulated by the Center for Biologics Evaluation and Research*: Elizabeth Callaghan, Center for Biologics Evaluation and Research (HFM–370), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–8963.

**SUPPLEMENTARY INFORMATION:**

#### I. Background

FDA is announcing the availability of a guidance for industry entitled ''Bar Code Label Requirements—Questions and Answers.'' In the **Federal Register** of February 26, 2004 (69 FR 9120), FDA issued a final rule that requires certain human drug and biological product